These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 3063268)
1. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Helve E; Tikkanen MJ Atherosclerosis; 1988 Aug; 72(2-3):189-97. PubMed ID: 3063268 [TBL] [Abstract][Full Text] [Related]
2. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754 [TBL] [Abstract][Full Text] [Related]
3. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656 [TBL] [Abstract][Full Text] [Related]
4. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Mellies MJ; Gartside PS; Glatfelter L; Vink P; Guy G; Schonfeld G; Glueck CJ Metabolism; 1980 Oct; 29(10):956-64. PubMed ID: 6999291 [No Abstract] [Full Text] [Related]
5. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. Am J Cardiol; 1990 Sep; 66(8):22B-30B. PubMed ID: 2206033 [TBL] [Abstract][Full Text] [Related]
6. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. Ojala JP; Helve E; Karjalainen K; Tarkkanen A; Tikkanen MJ Atherosclerosis; 1990 May; 82(1-2):85-95. PubMed ID: 2360923 [TBL] [Abstract][Full Text] [Related]
7. Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Raveh D; Israeli A; Arnon R; Eisenberg S Atherosclerosis; 1990 May; 82(1-2):19-26. PubMed ID: 2360916 [TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia. Durrington PN; Miller JP Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872 [TBL] [Abstract][Full Text] [Related]
9. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia. Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013 [TBL] [Abstract][Full Text] [Related]
10. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586 [TBL] [Abstract][Full Text] [Related]
11. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia. Cortese C; Marenah CB; Miller NE; Lewis B Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396 [TBL] [Abstract][Full Text] [Related]
12. Lipoprotein fractions and receptors: a role for probucol? Bilheimer DW Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051 [TBL] [Abstract][Full Text] [Related]
13. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol. Tikkanen MJ; Helve E; Nikkilä EA Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684 [TBL] [Abstract][Full Text] [Related]
14. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study]. Forti N; Ramires JA Arq Bras Cardiol; 1991 Sep; 57(3):253-61. PubMed ID: 1824203 [TBL] [Abstract][Full Text] [Related]
15. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. Ojala JP; Helve E; Ehnholm C; Aalto-Setälä K; Kontula KK; Tikkanen MJ J Intern Med; 1991 Nov; 230(5):397-405. PubMed ID: 1940775 [TBL] [Abstract][Full Text] [Related]
16. Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090 [TBL] [Abstract][Full Text] [Related]
17. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895 [TBL] [Abstract][Full Text] [Related]
18. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Leren TP; Hjermann I; Berg K; Leren P; Foss OP; Viksmoen L Atherosclerosis; 1988 Oct; 73(2-3):135-41. PubMed ID: 3056429 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Rezzonico L; Chiesa G; Sirtori CR Arteriosclerosis; 1989; 9(4):462-9. PubMed ID: 2751476 [TBL] [Abstract][Full Text] [Related]
20. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. O'Malley JP; Illingworth DR Metabolism; 1990 Feb; 39(2):150-4. PubMed ID: 2299987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]